164 related articles for article (PubMed ID: 37846574)
1. Evidence-based management of optic neuritis.
Bergeron E; Bouffard MA
Curr Opin Ophthalmol; 2024 Jan; 35(1):73-82. PubMed ID: 37846574
[TBL] [Abstract][Full Text] [Related]
2. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
Mult Scler Relat Disord; 2021 Nov; 56():103222. PubMed ID: 34461572
[TBL] [Abstract][Full Text] [Related]
3. [Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment].
Wildemann B; Horstmann S; Korporal-Kuhnke M; Viehöver A; Jarius S
Klin Monbl Augenheilkd; 2020 Nov; 237(11):1290-1305. PubMed ID: 33202462
[TBL] [Abstract][Full Text] [Related]
4. [OPTIC NEURITIS - CLASSIFICATION, MANAGEMENT AND TREATMENT].
Almer Z
Harefuah; 2022 Oct; 161(10):645-651. PubMed ID: 36315205
[TBL] [Abstract][Full Text] [Related]
5. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore.
Foo R; Yau C; Singhal S; Tow S; Loo JL; Tan K; Milea D
Asia Pac J Ophthalmol (Phila); 2022 Mar-Apr 01; 11(2):184-195. PubMed ID: 35533337
[TBL] [Abstract][Full Text] [Related]
6. Optic neuritis: current challenges in diagnosis and management.
Benard-Seguin E; Costello F
Curr Opin Neurol; 2023 Feb; 36(1):10-18. PubMed ID: 36630210
[TBL] [Abstract][Full Text] [Related]
7. The Treatment of Acute Optic Neuritis.
Keyhanian K; Chwalisz BK
Semin Ophthalmol; 2023 Aug; 38(6):511-514. PubMed ID: 37162276
[TBL] [Abstract][Full Text] [Related]
8. The neuro-ophthalmological manifestations of NMOSD and MOGAD-a comprehensive review.
Moheb N; Chen JJ
Eye (Lond); 2023 Aug; 37(12):2391-2398. PubMed ID: 36928226
[TBL] [Abstract][Full Text] [Related]
9. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
[TBL] [Abstract][Full Text] [Related]
10. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort.
Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
Eur J Neurol; 2022 Mar; 29(3):802-809. PubMed ID: 34799965
[TBL] [Abstract][Full Text] [Related]
11. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis-A Review.
Kaushik M; Burdon MA
J Neuroophthalmol; 2021 Dec; 41(4):e786-e795. PubMed ID: 33870945
[TBL] [Abstract][Full Text] [Related]
12. An update on optic neuritis.
Kraker JA; Chen JJ
J Neurol; 2023 Oct; 270(10):5113-5126. PubMed ID: 37542657
[TBL] [Abstract][Full Text] [Related]
13. [Typical and atypical optic neuritis].
Sheremet NL; Eliseeva DD; Kalashnikova AK; Zakharova MN
Vestn Oftalmol; 2023; 139(6):175-182. PubMed ID: 38235645
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.
Gospe SM; Chen JJ; Bhatti MT
Eye (Lond); 2021 Mar; 35(3):753-768. PubMed ID: 33323985
[TBL] [Abstract][Full Text] [Related]
15. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
[TBL] [Abstract][Full Text] [Related]
17. Clinical Course and Treatment Response of Neuromyelitis Optica Spectrum Disease: An 8-Year Experience.
Lin CW; Lin IH; Chen TC; Jou JR; Woung LC
Asia Pac J Ophthalmol (Phila); 2019; 8(3):206-210. PubMed ID: 30421588
[TBL] [Abstract][Full Text] [Related]
18. [Optic neuritis: aetiopathogenesis, diagnosis, prognosis and management].
Rodríguez-Acevedo B; Rovira A; Vidal-Jordana A; Moncho D; Pareto D; Sastre-Garriga J
Rev Neurol; 2022 Feb; 74(3):93-104. PubMed ID: 35084734
[TBL] [Abstract][Full Text] [Related]
19. [Effects of intravenous methylprednisolone pulse therapy on optic neuritis associated with AQP4 antibody seropositive neuromyelitis optica].
Guo ST; Li Z; Jiang LB; Wu RH; Peng JT; Wang JW; Wei WB
Zhonghua Yan Ke Za Zhi; 2019 Mar; 55(3):180-185. PubMed ID: 30841684
[No Abstract] [Full Text] [Related]
20. Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.
Saitakis G; Chwalisz BK
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
